U.S. markets open in 8 hours 25 minutes
  • S&P Futures

    3,857.00
    +12.00 (+0.31%)
     
  • Dow Futures

    31,156.00
    +60.00 (+0.19%)
     
  • Nasdaq Futures

    13,377.50
    +83.25 (+0.63%)
     
  • Russell 2000 Futures

    2,160.60
    +2.90 (+0.13%)
     
  • Crude Oil

    53.28
    +0.04 (+0.08%)
     
  • Gold

    1,873.40
    +6.90 (+0.37%)
     
  • Silver

    26.07
    +0.30 (+1.16%)
     
  • EUR/USD

    1.2137
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.58
    -1.66 (-7.14%)
     
  • GBP/USD

    1.3695
    +0.0061 (+0.45%)
     
  • USD/JPY

    103.3710
    -0.5210 (-0.50%)
     
  • BTC-USD

    34,586.79
    -75.82 (-0.22%)
     
  • CMC Crypto 200

    684.53
    -16.08 (-2.30%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,724.66
    +91.20 (+0.32%)
     

What Kind Of Shareholders Own Cidara Therapeutics, Inc. (NASDAQ:CDTX)?

Simply Wall St
·5 min read

A look at the shareholders of Cidara Therapeutics, Inc. (NASDAQ:CDTX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

With a market capitalization of US$105m, Cidara Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Cidara Therapeutics.

See our latest analysis for Cidara Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Cidara Therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Cidara Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Cidara Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 8.6% of Cidara Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Mundipharma International Limited is the largest shareholder with 11% of shares outstanding. BVF Partners, L.P. is the second largest shareholder owning 8.6% of common stock, and Bellevue Asset Management AG holds about 6.4% of the company stock. Furthermore, CEO Jeffrey Stein is the owner of 1.4% of the company's shares.

On further inspection, we found that more than half the company's shares are owned by the top 9 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Cidara Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

I can report that insiders do own shares in Cidara Therapeutics, Inc.. In their own names, insiders own US$2.2m worth of stock in the US$105m company. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a 23% stake in Cidara Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 11%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Cidara Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Cidara Therapeutics (of which 1 can't be ignored!) you should know about.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.